International Isotopes Inc. Files Q1 2024 10-Q Report

TL;DR

<b>International Isotopes Inc. reported Q1 2024 results with $1.1M revenue and $154K net income.</b>

AI Summary

INTERNATIONAL ISOTOPES INC (INIS) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Revenue for the three months ended March 31, 2024, was $1,103,425. Net income for the three months ended March 31, 2024, was $154,051. Earnings per share (diluted) for the three months ended March 31, 2024, were $0.01. Total assets as of March 31, 2024, were $519,787,870. Total debt as of March 31, 2024, was $9,497.

Why It Matters

For investors and stakeholders tracking INTERNATIONAL ISOTOPES INC, this filing contains several important signals. The filing provides a detailed look at the company's financial performance and position at the end of the first quarter of 2024. Investors can assess the company's revenue generation, profitability, and balance sheet strength based on the reported figures.

Risk Assessment

Risk Level: low — INTERNATIONAL ISOTOPES INC shows low risk based on this filing. The company's financial performance in Q1 2024 shows modest revenue and net income, with no significant immediate risks highlighted in the provided data.

Analyst Insight

Monitor future filings for revenue growth trends and operational efficiency improvements in the isotope production sector.

Financial Highlights

revenue

1,103,425

total Assets

519,787,870

total Debt

9,497

net Income

154,051

eps

0.01

Revenue Breakdown

Key Numbers

• 1,103,425 — Revenue (Three months ended March 31, 2024)
• 154,051 — Net Income (Three months ended March 31, 2024)
• 0.01 — EPS (Diluted) (Three months ended March 31, 2024)
• 519,787,870 — Total Assets (As of March 31, 2024)
• 9,497 — Total Debt (As of March 31, 2024)

Key Players & Entities

• INTERNATIONAL ISOTOPES INC (company) — Filer name
• INIS (company) — Ticker symbol
• IDAHO FALLS (company) — Business address city
• TX (company) — State of incorporation

FAQ

Industry Context

International Isotopes Inc. operates in the industrial instruments sector, specifically focusing on the production and distribution of isotopes for medical, research, and industrial applications.

Regulatory Implications

The company is subject to standard SEC reporting requirements for public companies, including the filing of quarterly (10-Q) and annual (10-K) reports.

What Investors Should Do

1. Analyze the year-over-year revenue and net income changes in the next quarterly filing.
2. Review the company's cash flow statement for insights into operational funding and investment activities.
3. Investigate any specific segment reporting if available in future filings to understand revenue drivers.

Key Dates

• 2024-03-31: Quarter End — Reporting period for the 10-Q filing
• 2024-05-15: Filing Date — Date the 10-Q was filed with the SEC

Year-Over-Year Comparison

This 10-Q filing covers the first quarter of 2024, providing updated financial data compared to previous periods.

Key Financial Figures

• $0.01 — , the number of shares of common stock, $0.01 par value, outstanding was 522,957,618
• $0.25 — onsecutive trading days is greater than $0.25 per share, the Company may redeem all o

Filing Documents

• inis20240331_10q.htm (10-Q) — 796KB
• ex_630415.htm (EX-31.1) — 9KB
• ex_630416.htm (EX-31.2) — 8KB
• ex_630417.htm (EX-32.1) — 5KB
• ex_630418.htm (EX-32.2) — 5KB
• 0001437749-24-016847.txt (&nbsp;) — 4588KB
• inis-20240331.xsd (EX-101.SCH) — 36KB
• inis-20240331_cal.xml (EX-101.CAL) — 42KB
• inis-20240331_def.xml (EX-101.DEF) — 278KB
• inis-20240331_lab.xml (EX-101.LAB) — 265KB
• inis-20240331_pre.xml (EX-101.PRE) — 302KB
• inis20240331_10q_htm.xml (XML) — 677KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements Unaudited Condensed Consolidated Balance Sheets at March 31, 2024 and December 31, 2023 3 Unaudited Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2024 and 2023 4 Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023 5 Unaudited Condensed Consolidated Statement of Stockholder ' s (Deficit) Equity for the Three Months Ended March 31, 2024 and 2023 6 Notes to Unaudited Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 4.

Controls and Procedures

Controls and Procedures 25

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 25 Item 1A.

Risk Factors

Risk Factors 25 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25 Item 5. Other Information 25 Item 6. Exhibits 26

Signatures

Signatures 27 2 Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (unaudited) March 31, December 31, 2024 2023 Assets Current assets Cash and cash equivalents $ 2,368,496 $ 2,688,141 Accounts receivable 1,355,362 1,469,298 Inventories 934,186 927,111 Prepaids and other current assets 479,844 672,934 Total current assets 5,137,888 5,757,484 Long-term assets Restricted cash 1,378,279 880,752 Property, plant and equipment, net 2,589,572 2,465,077 Capitalized lease disposal costs, net 676,168 688,462 Financing lease right-of-use asset 5,108 6,611 Operating lease right-of-use asset 2,150,807 2,183,988 Goodwill 1,384,255 1,384,255 Patents and other intangibles, net 3,497,234 3,538,458 Total long-term assets 11,681,423 11,147,603 Total assets $ 16,819,311 $ 16,905,087 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 671,388 $ 559,597 Accrued liabilities 1,331,148 1,482,179 Unearned revenue 977,168 932,682 Current portion of operating lease right-of-use liability 143,121 140,733 Current portion of financing lease liability 2,077 2,832 Current installments of notes payable 145,000 155,733 Current portion of mandatorily redeemable preferred stock 4,063,000 — Total current liabilities 7,332,902 3,273,756 Long-term liabilities Accrued long-term liabilities 65,625 75,000 Related party notes payable, net of current portion and debt discount 1,620,000 1,620,000 Notes payable, net of current portion 217,100 270,732 Asset retirement obligation 1,491,738 1,474,463 Operating lease right-of-use liability, net of current portion 2,054,823 2,091,511 Mandatorily redeemable convertible preferred stock — 4,063,000 Total long-term liabilities 5,449,286 9,594,706 Total liabilities 12,782,188 12,868,462 Stockholders' equity Common stock, $ 0.01 par value; 750,000,000 shares authorized; 521,889,765 and 519,787,8

View Full Filing

View this 10-Q filing on SEC EDGAR